tradingkey.logo
搜索

ImmuCell Corp

ICCC
添加自选
11.210USD
+0.150+1.36%
收盘 07-31 16:00美东报价延迟15分钟
101.40M总市值
亏损市盈率 TTM

关于 ImmuCell Corp 公司

ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).

ImmuCell Corp简介

公司代码ICCC
公司名称ImmuCell Corp
上市日期May 01, 1987
CEOte Boekhorst (Olivier)
员工数量69
证券类型Ordinary Share
年结日May 01
公司地址56 Evergreen Drive
城市PORTLAND
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编04103
电话12078782770
网址https://immucell.com/
公司代码ICCC
上市日期May 01, 1987
CEOte Boekhorst (Olivier)

ImmuCell Corp公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Michael F. Brigham
Mr. Michael F. Brigham
Director
Director
216.70K
--
Dr. David Scott Tomsche, M.D.
Dr. David Scott Tomsche, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
131.39K
-1.55%
Ms. Bobbi Jo Brockmann
Ms. Bobbi Jo Brockmann
Vice President - Sales and Marketing, Director
Vice President - Sales and Marketing, Director
8.52K
--
Mr. Bryan K. Gathagan
Mr. Bryan K. Gathagan
Independent Director
Independent Director
1.00K
--
Mr. Paul R. Wainman
Mr. Paul R. Wainman
Independent Director
Independent Director
--
--
Mr. Steven T. Rosgen
Mr. Steven T. Rosgen
Independent Director
Independent Director
--
--
Ms. Gloria J. Basse
Ms. Gloria J. Basse
Independent Director
Independent Director
--
--
Mr. Timothy C. Fiori
Mr. Timothy C. Fiori
Chief Financial Officer, Treasurer, Secretary, Director
Chief Financial Officer, Treasurer, Secretary, Director
--
--
Mr. Olivier te Boekhorst
Mr. Olivier te Boekhorst
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Michael F. Brigham
Mr. Michael F. Brigham
Director
Director
216.70K
--
Dr. David Scott Tomsche, M.D.
Dr. David Scott Tomsche, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
131.39K
-1.55%
Ms. Bobbi Jo Brockmann
Ms. Bobbi Jo Brockmann
Vice President - Sales and Marketing, Director
Vice President - Sales and Marketing, Director
8.52K
--
Mr. Bryan K. Gathagan
Mr. Bryan K. Gathagan
Independent Director
Independent Director
1.00K
--
Mr. Paul R. Wainman
Mr. Paul R. Wainman
Independent Director
Independent Director
--
--
Mr. Steven T. Rosgen
Mr. Steven T. Rosgen
Independent Director
Independent Director
--
--

常见问题

ImmuCell Corp的前五大股东是谁?

ImmuCell Corp 的前五大股东如下:Mr. Michael F. Brigham

有多少机构持有ImmuCell Corp(ICCC)的股份?

截至2026Q1,共有48家机构持有ImmuCell Corp的股份,合计持有的股份价值约为2.16M,占公司总股份的23.86%。与2025Q4相比,机构持股有所增加,增幅为228934.00。

哪个业务部门对ImmuCell Corp的收入贡献最大?

在2026Q1,First Defense® product line业务部门对ImmuCell Corp的收入贡献最大,创收27.45M,占总收入的99.29%。
tradingkey.logo
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有